Viral inactivation in hemotherapy: systematic review on inactivators with action on nucleic acids

The aim of this study was to conduct a systematic review on the photoinactivators used in hemotherapy, with action on viral genomes. The SciELO, Science Direct, PubMed and Lilacs databases were searched for articles. The inclusion criterion was that these should be articles on inactivators with acti...

Full description

Bibliographic Details
Main Authors: Sobral, Patricia Marial, Barros, Artur Emilio de Lima, Gomes, Ayla Maritcha Alves Silva, do Bonfim, Cristine Vieira
Format: Online
Language:English
Published: Associação Brasileira de Hematologia e Hemoterapia 2012
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3459627/
id pubmed-3459627
recordtype oai_dc
spelling pubmed-34596272012-10-04 Viral inactivation in hemotherapy: systematic review on inactivators with action on nucleic acids Sobral, Patricia Marial Barros, Artur Emilio de Lima Gomes, Ayla Maritcha Alves Silva do Bonfim, Cristine Vieira Review Article The aim of this study was to conduct a systematic review on the photoinactivators used in hemotherapy, with action on viral genomes. The SciELO, Science Direct, PubMed and Lilacs databases were searched for articles. The inclusion criterion was that these should be articles on inactivators with action on genetic material that had been published between 2000 and 2010. The key words used in identifying such articles were "hemovigilance", "viral inactivation", "photodynamics", "chemoprevention" and "transfusion safety". Twenty-four articles on viral photoinactivation were found with the main photoinactivators covered being: methylene blue, amotosalen HCl, S-303 frangible anchor linker effector (FRALE), riboflavin and inactin. The results showed that methylene blue has currently been studied least, because it diminishes coagulation factors and fibrinogen. Riboflavin has been studied most because it is a photoinactivator of endogenous origin and has few collateral effects. Amotosalen HCl is effective for platelets and is also used on plasma, but may cause changes both to plasma and to platelets, although these are not significant for hemostasis. S-303 FRALE may lead to neoantigens in erythrocytes and is less indicated for red-cell treatment; in such cases, PEN 110 is recommended. Thus, none of the methods for pathogen reduction is effective for all classes of agents and for all blood components, but despite the high cost, these photoinactivators may diminish the risk of blood-transmitted diseases. Associação Brasileira de Hematologia e Hemoterapia 2012 /pmc/articles/PMC3459627/ /pubmed/23049426 http://dx.doi.org/10.5581/1516-8484.20120056 Text en http://creativecommons.org/licenses/by-nc/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
repository_type Open Access Journal
institution_category Foreign Institution
institution US National Center for Biotechnology Information
building NCBI PubMed
collection Online Access
language English
format Online
author Sobral, Patricia Marial
Barros, Artur Emilio de Lima
Gomes, Ayla Maritcha Alves Silva
do Bonfim, Cristine Vieira
spellingShingle Sobral, Patricia Marial
Barros, Artur Emilio de Lima
Gomes, Ayla Maritcha Alves Silva
do Bonfim, Cristine Vieira
Viral inactivation in hemotherapy: systematic review on inactivators with action on nucleic acids
author_facet Sobral, Patricia Marial
Barros, Artur Emilio de Lima
Gomes, Ayla Maritcha Alves Silva
do Bonfim, Cristine Vieira
author_sort Sobral, Patricia Marial
title Viral inactivation in hemotherapy: systematic review on inactivators with action on nucleic acids
title_short Viral inactivation in hemotherapy: systematic review on inactivators with action on nucleic acids
title_full Viral inactivation in hemotherapy: systematic review on inactivators with action on nucleic acids
title_fullStr Viral inactivation in hemotherapy: systematic review on inactivators with action on nucleic acids
title_full_unstemmed Viral inactivation in hemotherapy: systematic review on inactivators with action on nucleic acids
title_sort viral inactivation in hemotherapy: systematic review on inactivators with action on nucleic acids
description The aim of this study was to conduct a systematic review on the photoinactivators used in hemotherapy, with action on viral genomes. The SciELO, Science Direct, PubMed and Lilacs databases were searched for articles. The inclusion criterion was that these should be articles on inactivators with action on genetic material that had been published between 2000 and 2010. The key words used in identifying such articles were "hemovigilance", "viral inactivation", "photodynamics", "chemoprevention" and "transfusion safety". Twenty-four articles on viral photoinactivation were found with the main photoinactivators covered being: methylene blue, amotosalen HCl, S-303 frangible anchor linker effector (FRALE), riboflavin and inactin. The results showed that methylene blue has currently been studied least, because it diminishes coagulation factors and fibrinogen. Riboflavin has been studied most because it is a photoinactivator of endogenous origin and has few collateral effects. Amotosalen HCl is effective for platelets and is also used on plasma, but may cause changes both to plasma and to platelets, although these are not significant for hemostasis. S-303 FRALE may lead to neoantigens in erythrocytes and is less indicated for red-cell treatment; in such cases, PEN 110 is recommended. Thus, none of the methods for pathogen reduction is effective for all classes of agents and for all blood components, but despite the high cost, these photoinactivators may diminish the risk of blood-transmitted diseases.
publisher Associação Brasileira de Hematologia e Hemoterapia
publishDate 2012
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3459627/
_version_ 1611912332272730112